Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 7/20 | 0.40 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101162 | 1.00 | CHRNA7 (0.61) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 | |
| SCHEMBL6099902 | 0.94 | CHRNA7 (0.53) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 | |
| SCHEMBL6101741 | 0.87 | CHRNA7 (0.64) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 | |
| SCHEMBL6101744 | 0.87 | CHRNA7 (0.64) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 | |
| SCHEMBL6101096 | 0.84 | CHRNA7 (0.58) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 | |
| SCHEMBL6098161 | 0.84 | CHRNA7 (0.58) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 | |
| SCHEMBL6101093 | 0.84 | CHRNA7 (0.58) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 | |
| SCHEMBL6101199 | 0.84 | CHRNA7 (0.58) | CHRNA7DRD4 | |
| SCHEMBL6637254 | 0.84 | CHRNA7 (0.58) | CHRNA7DRD4 | |
| SCHEMBL6098156 | 0.84 | CHRNA7 (0.58) | CHRNA7HTR3ADRD4SLC6A12SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | CHRNA7 1836/4885HTR3A 3325/4885DRD4 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.